BioWorld

April 14, 2008

PDL to Spin Off Biotech Assets into New Firm by End of Year

Nearly a month after taking steps to streamline the company, PDL BioPharma Inc. said it plans to spin off its biotechnology assets into a separate publicly traded firm. (BioWorld Today) Read More

Lung Cancer Phase III Trial Garners Antisoma $25M

Lower-Than-Expected Avastin Sales Mar Genentech's lst Quarter

NewCo News: Molecular LogiX Plans to Use (Dominant) Negativity for Good

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...